First among Equals?:Does drug treatment for dementia claim more than its fair share of resources?

Dementia

Volumn 2, Issue 1, 2003, Pages 7-19

  Heller, Tom ^a   Heller, Lisa ^b  

^a OPEN UNIVERSITY   (United Kingdom)

^b Longley Centre   (United Kingdom)

Author keywords

budgets; dementia; medication; pharmaceutical companies

Indexed keywords

EID: 84993813716     PISSN: 14713012     EISSN: None     Source Type: Journal    
DOI: 10.1177/147130120300200102     Document Type: Article

References (41)

1. Alzheimer’s Society (2002). Drugs for the treatment of dementia. www.alzheimers.org.uk/society/p_drugs.html
2. Audit Commission (2001). Forget me not: Mental health services for older people. London: Audit Commission.
3. Ballard, C., & O’Brien, J. (1999). Treating behavioural and psychological signs in Alzheimer’s disease: The evidence for current pharmacological treatments is not strong. British Medical Journal, 319, 138–139.
4. Barnett, E. (2000). Including the person with dementia in designing and delivering care. London: Jessica Kingsley.
5. Bilikiewicz, A. (2002) An open-label study to evaluate the safety, tolerability and efficacy of rivastigmine in patients with mild to moderate probable Alzheimer’s disease in the community setting. Medical Science Monitor, 8(2), 9–15.
6. Bradford Dementia Group (1997). Dementia Care Mapping Manual. Bradford: University of Bradford.
7. Bryant, J., Clegg, A., Nicholson, T., McIntyre, L., DeBroe, S., Gerard, K., & Waugh, N. (2001). Clinical and cost-effectiveness of donepezil, rivastigmine and galantamine for Alzheimer’s disease: A rapid and systematic review. Health Technology Assessment (Southampton, UK), 5(1), 1–137.
8. Burns, A., Dening, T., & Baldwin, R. (2001). Mental health problems. British Medical Journal, 322, 789–791.
9. Choudhry, N., Stelfox, H., & Detsky, A. (2002). Relationships between authors of clinical practice guidelines and the pharmaceutical industry. Journal of the American Medical Association, 287, 612–617.
10. Cookson, R., McDaid, D., & Maynard, A. (2001). Wrong SIGN, NICE mess: Is national guidance distorting allocation of resources? British Medical Journal, 321, 743–745.
11. Donaldson, C., Tarrier, N., & Burns, A. (1998). Determinants of carer stress in Alzheimer’s disease. International Journal of Geriatric Psychiatry, 13, 248–256.
12. Doyle, Y. (2001). Equity in the new NHS: Hard lessons from implementing a local healthcare policy on donepezil. British Medical Journal, 323, 222–224.
13. Drug and Therapeutics Bulletin (2000). Rivastigmine for Alzheimer’s disease. Drug and Therapeutics Bulletin, 38(2), 15–16.
14. Garattini, S. (2000). The risk of bias from omitted research. British Medical Journal, 321, 845–846.
15. Goldsmith, M. (1996). Hearing the voice of people with dementia: Opportunities and obstacles. London: Jessica Kingsley.
16. Gray, A., & Fenn, P. (1993). Alzheimer’s disease: The burden of the illness in England. Health Trends, 25, 31–37.
17. Hiatt, H. (1975). Protecting the medical commons: Who is responsible? New England Journal of Medicine, 293(5), 235–241.
18. Hunter, R., McGill, L., Bosanquet, N., & Johnson, N. (1997). Alzheimer’s disease in the United Kingdom: Developing patient and carer support strategies to encourage care in the community. Quality in Health Care, 6(3), 146–152.
19. Johnson, N., Davis, T., & Bosanquet, N. (2000). The epidemic of Alzheimer’s disease: How can we manage the costs? Pharmacoeconomics, 18(3), 215–223.
20. Karlawish, J., Klocinski, J., Merz, J., Clark, C., & Ash, D. (2000). Caregivers’ preferences for the treatment of patients with Alzheimer’s disease. Neurology, 55, 1008–1014.
21. Killick, J., & Allan, K. (2001). Communication and the care of people with dementia. Buckingham: Open University Press.
22. Kitwood, T. (1997). Dementia reconsidered: The person comes first. Buckingham: Open University Press.
23. Koepp, R., & Miles, S. (1999). Meta-analysis of Tacrine for Alzheimer’s disease: The influence of industry sponsors. Journal of the American Medical Association, 281, 2287-2287.
24. Lothian, K., & Philp, I. (2001). Maintaining the dignity and autonomy of older people in the healthcare setting. British Medical Journal, 322, 668–670.
25. Lowin, A., Knapp, M.R.J., & McCrone, P. (2001). Alzheimer’s disease in the UK: Comparative evidence on cost-of-illness and volume of health services research funding. International Journal of Geriatric Psychiatry, 16(12), 1143–1148.
26. McNamee, P., Gregson, B., Buck, D., Bamford, C., Bond, J., & Wright, K. (1999). Cost of formal care for frail older people in England: The resource implications of the MRC cognitive function and ageing study. Social Science and Medicine, 48, 331–341.
27. Melzer, D. (1998). New drug treatment for Alzheimer’s disease: Lessons for healthcare policy. British Medical Journal, 316, 762–764.
28. Mittelman, M., Ferris, S., Steinberg, G., Schulman, E., Mackell, J., & Ambinder, A. (1993). An intervention that delays institutionalisation of Alzheimer’s disease patients: Treatment of spouse care-givers. Gerontologist, 33, 730–740.
29. Moriarty, J. (1999). Use of community and long-term care by people with dementia in the UK: A review of some issues in service provision and carer and user preferences. Aging and Mental Health, 3(4), 311–319.
30. National Institute for Clinical Excellence (2001). Guidance on the use of Donepezil, Rivastgmine and Galantamine for the treatment of Alzheimer’s Disease. Technology Appraisal Guidance– No. 19. London: NICE.
31. O’Hara, R., Mumenthaler, M.S., & Yesavage, J.A. (2000). Update on Alzheimer’s disease: Recent findings and treatments. Western Journal of Medicine, 172, 115–120.
32. Qizilbash, N., & Arrieta, J. (1999). The Cochrane Dementia and Cognitive Impairment Group. Dementia Reviews, 2(1), 5–9.
33. Rawlins, M. (2001). About NICE. www.nice.org.uk (accessed 1 December 2001).
34. Reid, D., Ryan, T., & Enderby, P. (2001). What does it mean to listen to people with dementia? Disability and Society, 16(3), 377–392.
35. Smith, R. (2000). The failings of NICE. British Medical Journal, 321, 1363–1364.
36. Souetre, E., Thwaites, R., & Yeardley, H. (1999). Economic impact of Alzheimer’s disease in the United Kingdom. Cost of care and disease severity for noninstitutionalised patients with Alzheimer’s disease. British Journal of Psychiatry, 174, 5–55.
37. Spector, A., Orrell, M., Davies, S., & Woods, B. (1999). Developing an evidence based therapy programme. Journal of Dementia Care (September/October), 28–29.
38. Strategic Defence Review (2001). http://www.mod.uk/issues/sdr/Ministry of Defence (accessed 27 September 2002).
39. Warner, J., & Butler, R. (2001). Drugs for Alzheimer’s disease: More effective agents are needed. British Medical Journal, 323, 1127–1128.
40. Wilcock, G.K., Lilienfeld, S., & Gaens, E. (2000). Efficacy and safety of galantamine in patients with mild to moderate Alzheimer’s disease: Multicentre randomised controlled trial. British Medical Journal, 321, 1445–1449.
41. Wilkinson, D. (2002). Too many lose out on the dementia care they deserve. Geriatric Medicine, 32(2), 11–14.